Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of $61.
From the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment has offering of prescription medications and assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and associated services, which includes medical, pharmacy, dental, behavioural health, healthcare management capabilities. The Corporate segment involves in offering management and administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.